Articles related to PULMONARY ARTERIAL HYPERTENSION (PAH)

The oral suspension formulation was developed for patients who have difficulty swallowing the tablet form of the PDE5 inhibitor.

A quartet of current clinical trials involving first-in-class molecules and CRISPR gene editing show great promise. STELLAR investigates a fusion protein in PAH, CodeBreak 200 studies a first-in-class of KRAS inhibitor, EMERGENT-2 focuses on a new treatment for schizophrenia, and NCT04601051 studies a gene editing drug for one form of amyloidosis.

A 57-year-old woman is evaluated for a 4-month history of progressive exertionaldyspnea and occasional chest pain and palpitations. She has limited cutaneoussystemic sclerosis with Raynaud phenomenon and gastroesophageal refluxdisease. Click to see the physical and lab results and see if you can choose the bestnext step.